JP2017521433A - Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 - Google Patents

Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 Download PDF

Info

Publication number
JP2017521433A
JP2017521433A JP2017501004A JP2017501004A JP2017521433A JP 2017521433 A JP2017521433 A JP 2017521433A JP 2017501004 A JP2017501004 A JP 2017501004A JP 2017501004 A JP2017501004 A JP 2017501004A JP 2017521433 A JP2017521433 A JP 2017521433A
Authority
JP
Japan
Prior art keywords
nucleic acid
hbv
pharmaceutically acceptable
acid polymer
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017501004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521433A5 (enExample
Inventor
アンドリュー ヴァイヤン
アンドリュー ヴァイヤン
Original Assignee
レプリコール インコーポレーティッド
レプリコール インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017521433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by レプリコール インコーポレーティッド, レプリコール インコーポレーティッド filed Critical レプリコール インコーポレーティッド
Publication of JP2017521433A publication Critical patent/JP2017521433A/ja
Publication of JP2017521433A5 publication Critical patent/JP2017521433A5/ja
Priority to JP2020074639A priority Critical patent/JP6922030B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2017501004A 2014-07-10 2015-07-07 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法 Pending JP2017521433A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020074639A JP6922030B2 (ja) 2014-07-10 2020-04-20 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US62/022,846 2014-07-10
US201462091943P 2014-12-15 2014-12-15
US62/091,943 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020074639A Division JP6922030B2 (ja) 2014-07-10 2020-04-20 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法

Publications (2)

Publication Number Publication Date
JP2017521433A true JP2017521433A (ja) 2017-08-03
JP2017521433A5 JP2017521433A5 (enExample) 2018-08-16

Family

ID=55063440

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017501004A Pending JP2017521433A (ja) 2014-07-10 2015-07-07 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
JP2020074639A Active JP6922030B2 (ja) 2014-07-10 2020-04-20 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020074639A Active JP6922030B2 (ja) 2014-07-10 2020-04-20 Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法

Country Status (33)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR20170029577A (enExample)
CN (2) CN106659730A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512975A (ja) * 2018-11-08 2022-02-07 アリゴス セラピューティクス インコーポレイテッド Ｓ－抗原輸送阻害オリゴヌクレオチドポリマーおよび方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
EP4367241A1 (en) 2021-07-09 2024-05-15 GlaxoSmithKline Intellectual Property (No.3) Limited Use of oligonucleotides for individuals with renal impairment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170385A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex methods
WO2013170386A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
CN1694959B (zh) 2002-09-13 2013-09-18 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
HUE029521T2 (en) 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
EP3327125B1 (en) * 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170385A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex methods
WO2013170386A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAWLA, Y.K.: "Estimation of serum hepatitis B virus covalently closed circular DNA (HBV cccDNA) during treatment w", HEPATOLOGY INTERNATIONAL, vol. 8, no. 1, JPN6019011837, March 2014 (2014-03-01), pages 87, ISSN: 0004011735 *
JOURNAL OF HEPATOLOGY, vol. 54, JPN6019050193, 2011, pages 449 - 454, ISSN: 0004178004 *
横須賀收等: "B型慢性肝炎に対する核酸アナログ製剤治療の最新情報", 医学のあゆみ, vol. 242, no. 5, JPN6019011835, 2012, pages 421 - 426, ISSN: 0004011734 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512975A (ja) * 2018-11-08 2022-02-07 アリゴス セラピューティクス インコーポレイテッド Ｓ－抗原輸送阻害オリゴヌクレオチドポリマーおよび方法

Also Published As

Publication number Publication date
TW201613617A (en) 2016-04-16
HK1231402A1 (zh) 2017-12-22
ES2963814T3 (es) 2024-04-02
DOP2017000002A (es) 2017-03-15
BR112017000320B1 (pt) 2023-02-07
JP2020143065A (ja) 2020-09-10
US20160008393A1 (en) 2016-01-14
HUE064449T2 (hu) 2024-03-28
MD4760C8 (ro) 2022-02-28
KR20170029577A (ko) 2017-03-15
PH12017500010B1 (en) 2022-07-29
EP3166615B1 (en) 2023-08-09
PH12017500010A1 (en) 2017-05-15
EA201790160A1 (ru) 2017-06-30
RS64833B1 (sr) 2023-12-29
HRP20231400T1 (hr) 2024-02-16
MX381042B (es) 2025-03-12
IL249660B (en) 2022-02-01
CA2954182C (en) 2023-08-15
KR20230070330A (ko) 2023-05-22
BR112017000320A2 (pt) 2017-11-07
PL3166615T3 (pl) 2024-02-19
CA2954182A1 (en) 2016-01-14
CN106659730A (zh) 2017-05-10
WO2016004525A1 (en) 2016-01-14
PT3166615T (pt) 2023-11-13
SG11201700073PA (en) 2017-02-27
EP3166615A4 (en) 2018-01-17
LT3166615T (lt) 2024-01-25
MD20170014A2 (ro) 2017-07-31
NZ727583A (en) 2024-08-30
JP6922030B2 (ja) 2021-08-18
MY178087A (en) 2020-10-02
AU2015286199A1 (en) 2017-02-23
MD4760B1 (ro) 2021-07-31
EA036745B1 (ru) 2020-12-16
MX2017000053A (es) 2017-05-01
IL249660A0 (en) 2017-02-28
FI3166615T3 (fi) 2023-11-06
SMT202300380T1 (it) 2024-01-10
ECSP16097355A (es) 2017-03-31
CL2017000008A1 (es) 2017-06-09
TWI766831B (zh) 2022-06-11
US9603865B2 (en) 2017-03-28
CN113750112A (zh) 2021-12-07
DK3166615T3 (da) 2023-11-13
KR102734495B1 (ko) 2024-11-25
AU2015286199B2 (en) 2020-05-14
CU20170001A7 (es) 2017-04-05
EP3166615A1 (en) 2017-05-17
SI3166615T1 (sl) 2023-12-29

Similar Documents

Publication Publication Date Title
JP6922030B2 (ja) Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
JP6270846B2 (ja) Ｂ型肝炎感染及びｄ型肝炎感染の治療方法
CA3043637A1 (en) Oligonucleotide targeting strategy for hbv cccdna
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
CN114057816A (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
HK1210022B (zh) 治疗乙型肝炎及丁型肝炎感染的方法
EA039949B1 (ru) Способы лечения инфекций вирусом гепатита в и гепатита d

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191219